TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mechanical Pressure Pain Thresholds (MPPTh)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical Temporal Summation of Pain (MTSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement measured by change in Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional and clinical improvement measured by change in Quick- Disabilities of Arm, Shoulder and Hand Questionnaire (Q-DASH) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional and clinical improvement measured by change in Boston Carpal Tunnel Questionnaire (BCTQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Painfulness Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scoring of completed quality-of-life tests
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: determination of stress level and adaptation reserves of the organism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences and severity of AE
Endpoint domain: Adverse events/effects
Primary endpoint: Menstrual cycle regularity and frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Acne as a symptom of hyperandrogenism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Acne measure via expert skin grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Collection of real-world clinical data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful collection and translational analysis of biospecimens
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Refraction Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant changes in Eastern Co-operative Oncology Group (ECOG) performance status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant changes in relevant laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 Time Sit to Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days of broad-spectrum antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnosis of acute prosthetic joint infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: State-Trait Anxiety Inventory (STAI)-state questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: regression of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CNS Overall response rate (CORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of acute prosthetic joint infection (PJI)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed plasma (peak) concentration (Cmax) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time zero to the last quantifiable concentration (AUCt) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time zero extrapolated to infinity (AUC∞) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shortness of breath measured through borg scale of dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average total dose injected during all sessions of Dysport®
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median total dose injected during all sessions of Dysport®
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average interval between Dysport® injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Antibody levels measured by quantitative IgG assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of ITACITINIB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory hypersensitivity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central sensitization inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Peak Post-Administration Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Peak Post-Administration Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in Suicide Ideation Scores (Columbia Suicide Severity Rating Scale - Severity Factor)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urine weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Homeostatic Model Assessment for Insulin Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Craniovertebral Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in standing heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Femoral neck bone mineral content from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Femoral neck bone mineral density from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Numeric pain Rating scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Modification of bacterial diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: polyp number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: polyp size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isolate macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants with Success for Procedural Sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Intraoperative Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum PSA changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Solicited Administration Site Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting Solicited Systemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Intervention Appropriateness Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of Intervention Measure
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Provider Fidelity- Change since baseline in provider fidelity
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient Health Questionnaire-2 (PHQ-2)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 2 item Behavioral Activation for Depression Scale (BADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 50% effect concentration of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90% effect concentration of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with evidence of interbody fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Monocular refractive outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Activity of indoleamine 2, 3-dioxygenase (IDO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Time in Range (Phase 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Time in Range (Phase 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline total weight loss at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient comfort for MI Paste
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in patient comfort for Biotene Dry Mouth Gel
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in retention for MI Paste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in retention for Biotene Dry Mouth Gel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure to insert a radial artery catheter
Endpoint domain: Adverse events/effects
Primary endpoint: Fall Efficiency Scale-International (FES-I)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Modified Toronto Clinical Neuropathy Score (mTCNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical-microbiological course
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intensity of pain in residual and phantom limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of immune cause of recurrent implantation failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: efficiency of immunomodulatory treatment on pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Total mood scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of malignant and benign tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Root Mean Square Value (RMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Power Frequency (MPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractal Dimension (FD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope Sign Change (SSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spinal Reflex Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Shoulder rotators strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance reached with Single Arm Medicine Ball Throw
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional outcome using ASES score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PACU opioid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of eligible participants who enroll in study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants in experimental arm who complete intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants who complete all outcome measures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: superficial masseter muscles EMG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Active Mouth Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective symptom improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency and severity of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Emergency department presentation, observation, or hospitalization within 9 days
Endpoint domain: Mortality/survival
Primary endpoint: Predictive value of coincidence of TWR and NWSS for unruptured aneurysm rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Predictive value of serum TNF-α for unruptured aneurysm rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Predictive value of sex for unruptured aneurysm rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative 24 hours pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total plasma Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma Low density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Repetitive Nerve Stimulation difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Single Fiber Electro Myography (sfEMG) difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: first pass success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Cervical Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central retinal artery resistivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peak systolic velocity (cm/s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: End diastolic velocity (cm/s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Exercise intervention attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intervention fidelity in terms of compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Exercise relative dose intensity (ExRDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular stenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: WOMAC self-reported pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC self-reported function score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence rate of postherpetic neuralgia (PHN)
Endpoint domain: Adverse events/effects
Primary endpoint: Days at home within 90 days
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Breast cancer specific QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Seroconversion for SARS-CoV-2 neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in attention performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Moisturizing efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful resolution of LV thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of one day discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of stuttering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FiO2 threshold value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects with dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of PSMA+ subjects with PSA decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of meeting at least 80% of the required cell dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of meeting the required produce release criteria
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in dynamic cerebral autoregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time until the mouth is free of food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Control rate of non-irradiated area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevention of symptomatic RT-PCR-positive COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in peripheral oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acetaminophen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular response defined as ≥ 30% decrease from baseline in circulating tumor DNA (ctDNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST)
Endpoint domain: Mortality/survival
Primary endpoint: Change in plasma neurofilament light concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in purposeful soccer heading frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Omega-3 status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hepatic and renal toxic events
Endpoint domain: Adverse events/effects
Primary endpoint: relapses of Infective Endocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: patients requiring cardiac surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of CR-PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nighttime infant sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Total infant sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of infant night wakings
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: need for re-intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: weaning success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of 18F-PSMA PET/MRI for csPCa diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of csPCa missed by imaging modalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in detection of clinically insignificant PCa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood biomarkers levels 3-6 months postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Successful completion of cases using the augmented reality needle guidance system
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Procedure related adverse events within 7 days of the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hemorrhage Quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to the first episode of gonorrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: Time to the first episode of chlamydia
Endpoint domain: Adverse events/effects
Primary endpoint: Time to the first episode of syphilis
Endpoint domain: Adverse events/effects
Primary endpoint: Time prior to RDE prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Pittsburgh Sleep Quality Index global score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Subjective sleep efficiency (sSE)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Healthy Eating Index (HEI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for Care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in DMN resting state functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DMN-FPCN anticorrelation in resting state functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes